Clinical trials: MEK Mutation

RAS Mutation, Ras (Kras or Nras) Gene Mutation

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

• Unknown status
• Age: 18 to 85 years
• Phase 2

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the…

Conditions

RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent, Pancreas Cancer

Trial name

NТО-RAS (NCT06229340)

Testing

Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab

Where

Russia

Volunteers

20 people, healthy volunteers welcome

Sponsor

N.N. Petrov National Medical Research Center of Oncology